Table 2.
SNP | Genotype | Healthy controls (n = 253) |
T2D patients (n = 234) |
CAD patients (n = 200) |
T2D &CAD patients (n = 185) | HWEa | p valueb | Additive model, p valuec | Dominant model, p valuec |
---|---|---|---|---|---|---|---|---|---|
rs174537G>T | GG | 65 | 88 | 58 | 63 | 0.56 | 0.009 | 0.032 | 0.027 |
GT | 131 | 106 | 90 | 91 | |||||
TT | 57 | 40 | 52 | 31 | |||||
rs174616C>T | CC | 113 | 104 | 88 | 99 | 0.59 | 0.383 | 0.445 | 0.180 |
TC | 115 | 109 | 90 | 68 | |||||
TT | 25 | 21 | 22 | 18 | |||||
rs174460C>T | TT | 151 | 129 | 106 | 112 | 0.56 | 0.185 | 0.136 | 0.344 |
TC | 91 | 81 | 78 | 56 | |||||
CC | 11 | 24 | 16 | 17 | |||||
rs174450A>C | AA | 101 | 86 | 82 | 80 | 0.46 | 0.550 | 0.743 | 0.589 |
AC | 122 | 113 | 96 | 80 | |||||
CC | 30 | 35 | 22 | 25 |
aHardy–Weinberg Equilibrium (HWE) was calculated in healthy controls
b p values derived from the Chi square test of allele frequency
c p values derived from the Chi square test of genotype distribution